2020 | HFSA

Assessing the Lifetime Benefit of Heart Failure Therapies

Practice News Research

In a landmark essay redefining world systems analysis, Fernand Braudel observed in 1958 that the perceived crisis in the human sciences at that time was largely a result of their success and the rapid pace of additions to the knowledge base. 1 He encouraged colleagues to incorporate a longer historical view, the longue durée, and to embrace multidisciplinary approaches to inform their understanding. Many physicians may be overwhelmed by the success of contemporary heart failure therapeutics, with multiple trials of medicines demonstrating improved survival and decreased morbidity in patients with heart failure with reduced ejection fraction (HFrEF). Unfortunately, few patients are treated with the ideal, guideline-directed cocktail of these medications.

Read the full article in The Lancet >>